| 產品名稱 |
BA7.3C.9 |
| 商品貨號 |
B163990 |
| Organism |
Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Cell Type |
hybridoma: B lymphocyte |
| Product Format |
frozen |
| Morphology |
lymphoblast |
| Culture Properties |
suspension |
| Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease |
Erythroleukemia |
| Strain |
Strain: BALB/c (B cell); BALB/c (myeloma) |
| Applications |
The antibody is specific for human stem cell factor (hSCF) receptor. |
| Disclosure |
This material is cited in a US or other Patent and may not be used to
infringe the claims. Depending on the wishes of the Depositor, ATCC may be
required to inform the Patent Depositor of the party to which the material was
furnished. This material may not have been produced or characterized by ATCC. |
| Derivation |
Spleen cells were fused with NS-1 mouse myeloma cells. |
| Genes Expressed |
immunoglobulin; monoclonal antibody; against human stem cell factor (hSCF) receptor (CD117) |
| Cellular Products |
immunoglobulin; monoclonal antibody; against human stem cell factor (hSCF) receptor (CD117) |
| Tumorigenic |
Yes |
| Effects |
Yes, forms ascites in pristane primed BALB/c mice |
| Comments |
Animals were immunized with the erythroleukemia cell line OCIM1 because of their high SCF receptor display. Spleen cells were fused with NS-1 mouse myeloma cells. The antibody is specific for human stem cell factor (hSCF) receptor. |
| Complete Growth Medium |
The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
| Subculturing |
Medium Renewal: Every 2 to 3 days Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 X 10 exp5 viable cells/ml. Maintain cell density between 1 X 10 exp5 and 1 X 10 exp6 viable cells/ml. |
| Cryopreservation |
culture medium 95%; DMSO, 5% |
| Culture Conditions |
Temperature: 37.0°C |
| Isotype |
IgG2a |
| Name of Depositor |
Amgen, Inc. |
| Deposited As |
mouse (B cell); mouse (myeloma) |
| U.S. Patent Number |
|
| References |
Broudy VC, Lin N. Method of reconstituting hematopoietic cells using monoclonal antibodies to the stem cell factor receptor. US Patent 5,906,938 dated May 25 1999
Broudy VC, Lin N. Monoclonal antibodies to stem cell factor receptors. US Patent 5,919,911 dated Jul 6 1999
|
